[含利福布汀的长疗程化疗方案治疗耐多药肺结核的对照临床试验]
[A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis].
作者信息
Zhu Li-zhen, Fu Yu, Chu Nai-hui, Ye Zhi-zhong, Xiao He-ping, Wang Wei, Yuan Song-lin, Zhang Xia, Luo Yong-ai, Ma Li-ping
机构信息
Department of Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
出版信息
Zhonghua Jie He He Hu Xi Za Zhi. 2006 Aug;29(8):520-3.
OBJECTIVE
To evaluate the curative effect and safety of a long course regimen containing Chinese-made rifabutin as compared to the regimen containing rifapentine in the treatment of multi-drug resistant pulmonary tuberculosis.
METHOD
During 18 month treatment, 130 patients with multi-drug resistant pulmonary tuberculosis were divided into a treatment group (rifabutin, pasiniazide, levofloxacin, ethambutol, ethionamide, amikacin for 3 months, rifabutin, pasiniazide, levofloxacin, ethambutol, ethionamide for 6 months, rifabutin, pasiniazide, levofloxacin, ethambutol for 9 months), and a control group (rifapentine, pasiniazide, levofloxacin, ethambutol, ethionamide, amikacin for 3 months, rifabutin, pasiniazide, levofloxacin, ethambutol, ethionamide for 6 months, rifabutin, pasiniazide, levofloxacin, ethambutol for 9 months) with proportion 1:1 random, and parallel compared method.
RESULTS
After intensive phase, the sputum negative conversion rates (smear negative, culture negative) of the treatment group and the control group were 41.54% (27/65) and 35.94% (23/65), chi(2) = 2.42, P > 0.05, respectively. The remarkable effective rates in chest X-ray of the two groups were all 10.77% (7/65), chi(2) = 0.01, P > 0.05, and the effective rates were 67.69% (44/65) and 56.92% (37/65), chi(2) = 1.44, P > 0.05, respectively. At the end of the treatment, the sputum negative conversion rate (smear negative, culture negative) of the treatment group was 75.0% (48/65), and of the control group was 65.08% (41/65), chi(2) = 1.88, P > 0.05. The remarkable effective rates in chest X-ray of the two groups were 46.15% (30/65) and 44.62% (29/65), chi(2) = 0.02, P > 0.05, and the effective rates were 76.92% (50/65) and 73.85% (48/65), chi(2) = 0.19, P > 0.05, respectively. The cavity closure rates were 23.64% (13/55) and 33.33% (17/51), chi(2) = 0.00, P > 0.05, respectively.
CONCLUSION
Regimens containing rifabutin or rifapentine. are very effective in sputum negative conversion rate, lesion absorption and cavity closing for the treatment of multi-drug resistant pulmonary tuberculosis, with good safety and tolerance.
目的
评价含国产利福布汀的长程方案与含利福喷汀方案治疗耐多药肺结核的疗效及安全性。
方法
18个月治疗期间，将130例耐多药肺结核患者按1:1随机分为治疗组（利福布汀、帕司烟肼、左氧氟沙星、乙胺丁醇、丙硫异烟胺、阿米卡星3个月，利福布汀、帕司烟肼、左氧氟沙星、乙胺丁醇、丙硫异烟胺6个月，利福布汀、帕司烟肼、左氧氟沙星、乙胺丁醇9个月）和对照组（利福喷汀、帕司烟肼、左氧氟沙星、乙胺丁醇、丙硫异烟胺、阿米卡星3个月，利福布汀、帕司烟肼、左氧氟沙星、乙胺丁醇、丙硫异烟胺6个月，利福布汀、帕司烟肼、左氧氟沙星、乙胺丁醇9个月），采用平行对照法。
结果
强化期后，治疗组和对照组痰菌阴转率（涂片阴性、培养阴性）分别为41.54%（27/65）和35.94%（23/65），χ² = 2.42，P > 0.05。两组胸部X线显著有效率均为10.77%（7/65），χ² = 0.01，P > 0.05，有效率分别为67.69%（44/65）和56.92%（37/65），χ² = 1.44，P > 0.05。治疗结束时，治疗组痰菌阴转率（涂片阴性、培养阴性）为75.0%（48/65），对照组为65.08%（41/65），χ² = 1.88，P > 0.05。两组胸部X线显著有效率分别为46.15%（30/65）和44.62%（29/65），χ² = 0.02，P > 0.05，有效率分别为76.92%（50/65）和73.85%（48/65），χ² = 0.19，P > 0.05。空洞闭合率分别为23.64%（13/55）和33.33%（17/51），χ² = 0.00，P > 0.05。
结论
含利福布汀或利福喷汀的方案在耐多药肺结核治疗的痰菌阴转率、病灶吸收及空洞闭合方面疗效显著，安全性及耐受性良好。
Zotero 插件